EXHIBIT 99.2

CONSOLIDATED FINANCIAL STATEMENTS

Oceana Therapeutics, Inc.

For the Quarterly Period Ended September 30, 2011

Oceana Therapeutics, Inc.

Unaudited Consolidated Financial Statements

Nine Months Ended September 30, 2011

Contents

Oceana Therapeutics, Inc.

Unaudited Consolidated Balance Sheets

See accompanying notes to unaudited consolidated financial statements.

1

Oceana Therapeutics, Inc.

Consolidated Statements of Operations (Unaudited)

See accompanying notes to unaudited consolidated financial statements.

2

Oceana Therapeutics, Inc.

Consolidated Statements of Cash Flows (Unaudited)

See accompanying notes to unaudited consolidated financial statements.

3

Oceana Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

September 30, 2011

1. Description of Business and Significant Accounting Policies

Organization

Oceana Therapeutics, Inc. (the “Company”) is a privately owned, global healthcare company committed to commercializing best-in-class therapeutics with a focus on colorectal, gastroenterology and urological diseases. The Company’s activities have consisted of the marketing and sales of two medical device products.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying consolidated financial statements include all adjustments (including normal recurring accruals) considered necessary for fair presentation of the Company’s consolidated financial position, results of operations and cash flows for the periods presented. Operating results for the current interim period are not necessarily indicative of the results that may be expected for the year ended December 31, 2011. These financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2010.

The unaudited consolidated financial statements include the accounts of Oceana Therapeutics, Inc. and its wholly owned subsidiary, Oceana Therapeutics Limited. Intercompany transactions and balances are eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents.

4

Oceana Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements (continued)

1. Description of Business and Significant Accounting Policies (continued)

Restricted Cash

Restricted cash collateralizes outstanding letters of credit associated with a lease for office space in Edison, New Jersey. The funds are invested in certificates of deposit. The letter of credit permits draws by the landlord to cure defaults by the Company. Additionally, the restricted cash is collateralized with a certificate of deposit, in the event the Company defaults in its obligations under foreign exchange contracts with a financial institution.

Income Taxes

The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. The nine-month period ended September 30, 2011 includes the tax effect of netting the deferred tax liabilities with deferred tax assets. Prior to the approval of Solesta^® in the United States, the Company was not able to predict the timing of the reversal of this temporary difference. The net impact of this change in estimate was a realization of deferred tax assets of approximately $1.1 million.

Comprehensive Income (Loss)

Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes changes in the fair value of the Company’s cash flow hedges and foreign exchange translation adjustments. The following table sets forth the components of comprehensive income (loss):

5

Oceana Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements (continued)

2. Foreign Exchange Forward Contracts

The Company, in the normal course of business, periodically enters into foreign exchange forward contracts to reduce the risk associated with currency movements (primarily between the U.S. Dollar, the Euro and Swedish Krona) related to committed inventory purchases denominated in foreign currency. The Company does not enter into these contracts for the purpose of trading or speculation. The fair value of foreign currency contract derivatives is based on quoted prices for similar assets or liabilities in active markets adjusted for nonperformance risk.

The Company designates its forward foreign currency contracts as effective cash flow hedges. In order to qualify as effective cash flow hedges, the Company’s forward foreign currency contracts must satisfy various criteria. Those criteria include documenting, at inception, the hedging relationship and the risk management objective and strategy for undertaking the hedge. This documentation includes identifying the hedged instrument, the hedged transaction, the nature of the risk being hedged, and how the hedging instrument’s effectiveness in hedging the exposure to the hedged transaction’s variability in cash flows attributable to the hedged risk will be assessed. In addition, the forecasted transactions that are being hedged are specifically identifiable and the occurrence of the forecasted transactions is probable. The critical terms of the Company’s foreign currency contracts are the same as the underlying forecasted transactions; therefore, changes in the fair value of the contracts should be highly effective in offsetting changes in the expected cash flows from the forecasted transactions. Accordingly, changes in the fair value of forward exchange contracts are recorded in other comprehensive income (loss), net of related tax effects, with the corresponding asset or liability recorded in the consolidated balance sheets.

The valuation of the Company’s derivative financial instruments is based on similar instruments quoted in the open market.

For all hedging activities, the ineffective portion of a derivative’s change in fair value is immediately recognized in other income (expense). For derivative instruments not designated as hedging instruments, the gain or loss is recognized in other income (expense) during the period of change. The Company believes that any such non-designated instruments would offset the economic risks of the hedged items. Ineffectiveness of the hedged items is not significant.

6

Oceana Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements (continued)

2. Foreign Exchange Forward Contracts (continued)

At September 30, 2011, the notional amounts and estimated fair values, using quotes from external sources (Level 2), of the Company’s outstanding forward foreign currency contracts are detailed below:

Cost of sales includes a loss of $30,259 for the period ended September 30, 2011 and a gain of $23,936 for the period ended September 30, 2010, related to the settlement of foreign denominated inventory purchases.

The following tables set forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis at September 30, 2011 by level within the fair value hierarchy. As required by ASC 820, Fair Value Measurements and Disclosures, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

7

Oceana Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements (continued)

2. Foreign Exchange Forward Contracts (continued)

There has been a change in fair value of the Company’s Level 3 contingent purchase price during the period ended September 30, 2011.

The following is a reconciliation of the beginning and ending balances of Level 3 contingent consideration.

The significant assumptions used in preparing the valuation of the Company’s contingent considerations as of September 30, 2011 include (i) discount rate (35%), (ii) risk-free interest rate (20-year U.S. Treasury yield of 3.4%), (iii) market risk premium (5.5%), (iv) premium for small size (12.7%), and (v) probability of success (100%).

8

Oceana Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements (continued)

2. Foreign Exchange Forward Contracts (continued)

If the Company’s estimates regarding the fair value of these future considerations are inaccurate, a future adjustment to these estimated fair values may be required. Additionally, these estimated fair values could change significantly.

3. Intangible Assets

The intangible assets with definite lives consist of Deflux^® and Solesta^® patents. These intangible assets are being amortized on the straight-line method over their estimated useful lives of six years. Amortization expense related to intangible assets was approximately $7.9 million and $6.9 million for the periods ended September 30, 2011 and 2010, respectively. Starting June 2011, after approval of Solesta^® in the United States, the in-process research and development intangible asset was reclassified to the Solesta intangible asset with a definite life and the Company began amortization of this asset.

The Company’s intangible assets consist of the following (in thousands):

The weighted average amortization period for intangible assets subject to amortization is four years at September 30, 2011 and five years at December 31, 2010.

9

Oceana Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements (continued)

4. Property and Equipment

Property and equipment consisted of the following at September 30, 2011:

Included in the net book value of property, plant and equipment at September 30, 2011 was $44,913 of assets financed through an auto loan. Depreciation expense was $160,265 and $166,772 for the periods ended September 30, 2011 and 2010, respectively.

5. Capital Structure

Common Stock

As of September 30, 2011, common stock consisted of the following:

In June 2011, the Company raised $25.0 million of capital funds, the proceeds of which were used to pay the milestone payment due Q-Med Scandinavia Inc. triggered by the approval of Solesta^® in the United States and for general corporate purposes. No additional shares were issued as a result of this raise, so all of the funds are considered additional paid-in capital.

10

Oceana Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements (continued)

5. Capital Structure (continued)

Equity Units

During 2009, the Company’s Board of Directors approved an Equity Unit Appreciation Plan (the “2009 Plan”). Pursuant to the 2009 Plan, the Company granted profit interests (the “Equity Units”) to certain of its executives and employees. The Equity Units have two subclasses: Service Units and Performance Units. Subject to forfeiture and participation provisions, as detailed in the 2009 Plan, the holders of Equity Units shall have rights with respect to profits of the Company upon a qualifying event. The Equity Units are not convertible into common stock and are not saleable or generally transferable.

The Company’s Board of Directors approved 4,055,627 Equity Units, as defined, available for grant, of which 3,021,000 Equity Units have been granted. The Equity Units were granted to the holders at no cost.

In total, 16.67% of the Equity Units granted were Service Units and the remaining 83.33% of the Equity Units granted were Performance Units. These grants participate in the Company’s profits only upon certain change of control or liquidation events and only if, upon the occurrence of such an event, Kelso Investment Associates VIII, L.P. receives an internal rate of return, compounded annually, on its investment in Oceana Therapeutics, LLC (“LLC”) of at least 8% and the Final Value, as defined in the Oceana Therapeutics LLC Agreement, is at least greater than 2.0 times the Initial Value, as defined in the Oceana Therapeutics LLC Agreement. All Equity Units will participate in distributions if the Final Value is greater than 4.5 times the Initial Value, and the Equity Units will participate in profits and losses on a ratable basis in the event that the Final Value is greater than 2.0 times, but less than 4.5 times the Initial Value. Equity Units granted to an executive or employee are subject to forfeiture if the executive or employee ceases to be employed by the Company prior to a change in control. Equity Units not eligible to participate in distributions are automatically forfeited.

11

Oceana Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements (continued)

5. Capital Structure (continued)

A summary of the Equity Units granted during the period ended September 30, 2011 is presented below:

No compensation expense will be recognized for the Service Units and Performance Units until a change in equity control is probable as the exercisability and number of units to be received is contingent upon that event. Accordingly, compensation expense relating to the fair value of the Service Units and Performance Units will be measured and recorded upon the occurrence of a change in control. Refer to the value of the unit as described in Note 7.

6. Operating Leases and Commitments

Rent expense under operating leases was $244,569 and $197,232 for the periods ended September 30, 2011 and 2010, respectively.

The Company is contractually obligated to make potential future success-based development, regulatory and commercial milestone payments in conjunction with acquisitions. These payments are contingent upon the occurrence of certain future events. The amount and the probability of contingent payments have been reflected on the Company’s consolidated financial statements. The contingent purchase price adjustment was $5,078,175 and $1,205,438 for the nine months ended September 30, 2011 and 2010, respectively.

If the Company’s estimates regarding the fair value of the future considerations are inaccurate, a future adjustment to these estimated fair values may be required.

12

Oceana Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements (continued)

7. Subsequent Events

On November 8, 2011, LLC announced it had entered into a definitive agreement for the sale of its operating subsidiary, the Company, to Salix Pharmaceuticals. Ltd. The all cash transaction was valued at approximately $313.7 million, less closing expenses of approximately $4.9 million, and was subject to Federal Trade Commission regulatory approval. The transaction was subsequently approved and the transaction closed as of end of day on December 19, 2011 (“Closing”). The approximate $308.8 million earned by the partners of the LLC and employees of the Company was further offset by two escrow reserves totaling approximately $30.9 million, leading to a total net payment of $277.9 million at Closing. All Equity Units granted under the Company’s Equity Unit Appreciation Plan, including the Service Units and the Performance Units, were subject to forfeiture and had no economic value until a qualifying event was realized, which did not take place until Closing. Therefore, no Fair Value was assigned to these Units as of September 30, 2011 and no compensation expense recognized for the nine months ended September 30, 2010 or September 30, 2011. Upon closing of the transaction, the total number of vested Service Units and Performance Units was 4,721,313 and 23,606,565, respectively. The per unit value for both was $2.272.

13